Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept.

Recent advances in combinatorial protein engineering have made it possible to develop immunoglobulin (Ig)-based and non-Ig protein scaffolds that can potentially substitute for most whole antibody-associated properties and currently translate into biologicals with drug-like properties. During the past 10 years, the most validated scaffolds have reached the clinical development phase and, recently, one of them [Kalbitor(®) (Dyax)] has made it to the market, making these alternative scaffold proteins viable drug candidates in a post-antibody landscape. Interestingly, several scaffolds include an immune-active component as part of their therapeutic mode of action, which yielded spectacular clinical efficacy in some hematological malignancies. Here, we review the most recent clinical advances and analyze their benefits for patients.

[1]  A. Patat,et al.  A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group. , 2010, British journal of clinical pharmacology.

[2]  Michael Hust,et al.  Phage display derived therapeutic antibodies. , 2008, Current pharmaceutical biotechnology.

[3]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[4]  L. Wyns,et al.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Kaye,et al.  An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies , 2009, Proceedings of the National Academy of Sciences.

[6]  S. Ståhl,et al.  Non-immunoglobulin based protein scaffolds. , 2011, Current opinion in biotechnology.

[7]  J. Hall,et al.  Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. , 2009, Biotechnology advances.

[8]  M. Little,et al.  Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. , 2000, Cancer research.

[9]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[10]  T. Mikkelsen,et al.  Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). , 2010 .

[11]  P. Kufer,et al.  BiTE: a new class of antibodies that recruit T-cells , 2008 .

[12]  A. Quaas,et al.  A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. , 2012 .

[13]  Z. Elgundi,et al.  Anti-TNFα domain antibody construct CEP-37247 , 2010, mAbs.

[14]  C. Jorcyk,et al.  Cancer Management and Research Dovepress Clinical Significance of Interleukin (il)-6 in Cancer Metastasis to Bone: Potential of Anti-il-6 Therapies , 2022 .

[15]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Jiskoot,et al.  Immunogenicity of Therapeutic Proteins: The Use of Animal Models , 2011, Pharmaceutical Research.

[17]  P. Carter,et al.  Introduction to current and future protein therapeutics: a protein engineering perspective. , 2011, Experimental cell research.

[18]  Lucy J. Holt,et al.  Domain antibodies: proteins for therapy. , 2003, Trends in biotechnology.

[19]  Andreas Plückthun,et al.  Ribosome display: a perspective. , 2012, Methods in molecular biology.

[20]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[21]  P. Baeuerle,et al.  Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. , 2011, Experimental cell research.

[22]  T Wurch,et al.  Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation. , 2008, Current pharmaceutical biotechnology.

[23]  R. Kontermann,et al.  Dual targeting strategies with bispecific antibodies , 2012, mAbs.

[24]  Shohei Koide,et al.  Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. , 2012, Journal of molecular biology.

[25]  Michaela Gebauer,et al.  Anticalins small engineered binding proteins based on the lipocalin scaffold. , 2012, Methods in enzymology.

[26]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[27]  P. Moore,et al.  Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.

[28]  W. Stemmer,et al.  Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature biotechnology.

[29]  B. Frangione,et al.  Franklin's disease: Ig gamma 2 H chain mutant BUR. , 1992, Journal of immunology.

[30]  E. Souied,et al.  Phase I Mp0112 Wet AMD Study: Results Of A Single Escalating Dose Study With DARPin® MP0112 In Wet AMD , 2011 .

[31]  H. Revets,et al.  The development of nanobodies for therapeutic applications. , 2009, Current opinion in investigational drugs.

[32]  John Löfblom,et al.  Bacterial display in combinatorial protein engineering , 2011, Biotechnology journal.

[33]  G. Sinha.  Ablynx drops lead nanobody , 2012, Nature Biotechnology.

[34]  H. Schellekens.  How to predict and prevent the immunogenicity of therapeutic proteins. , 2008, Biotechnology annual review.

[35]  Andreas Plückthun,et al.  DARPins and other repeat protein scaffolds: advances in engineering and applications. , 2011, Current opinion in biotechnology.

[36]  G. Henze,et al.  Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia , 2011, Leukemia.

[37]  C. Rader.  DARTs take aim at BiTEs. , 2011, Blood.

[38]  P. Hoffmann,et al.  CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. , 2007, Molecular immunology.

[39]  Felix Kratz,et al.  Clinical impact of serum proteins on drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[40]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[41]  A. Plückthun,et al.  Stabilizing ionic interactions in a full-consensus ankyrin repeat protein. , 2008, Journal of molecular biology.

[42]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[43]  A. Skerra.  Engineered protein scaffolds for molecular recognition , 2000, Journal of molecular recognition : JMR.

[44]  A. Koide,et al.  Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. , 2002, Protein engineering.

[45]  Gopi Shankar,et al.  Scientific and regulatory considerations on the immunogenicity of biologics. , 2006, Trends in biotechnology.

[46]  Arne Skerra,et al.  Anticalins®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies , 2007, Expert review of clinical immunology.

[47]  K Dane Wittrup,et al.  Yeast surface display for protein engineering and characterization , 2007, Current Opinion in Structural Biology.

[48]  A. Tolcher,et al.  Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin , 2011, Clinical Cancer Research.

[49]  Anthony Williams,et al.  DX-88 and HAE: a developmental perspective. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.